Gavilimomab

Gavilimomab (also known as ABX-CBL) is a mouse monoclonal antibody intended for use as an immunosuppressive biologic treatment of glucocorticoid-resistant graft versus host disease. It binds to the antigen CD147.^[1] Gavilimomab proved slightly less effective than standard antithymocyte globulin therapy.^[2]

Gavilimomab

Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	CD147
Clinical data
ATC code	none
Identifiers
CAS Number	244096-20-6 N
ChemSpider	none
UNII	TCR92293RC
NY (what is this?)  (verify)

It was originally developed by Abgenix,^[1] which was later acquired by Amgen.